Novo’s CagriSema reduces ‘food noise’; benefits organ and bone health

Danish pharma major Novo (NOV: N) today announced new data on how CagriSema (cagrilintide and semaglutide) works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.

In a 52-week functional magnetic resonance imaging (fMRI) study, a brain scan technique that shows how the brain responds to cues, in adults with overweight or obesity, CagriSema modified brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing and behavioural control. Additionally, CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment.